Enliven Therapeutics Inc.

---

Enliven Therapeutics has cash runway into late 2026

 November 16, 2024 10:58:46 am

---

Enliven Therapeutics begins patient dosing in oncology drug trial

 August 14, 2024 2:32:19 pm

---

Enliven has cash runway into late 2026

 May 15, 2024 2:16:39 pm

---

Enliven Therapeutics adds physician to board

 April 14, 2024 5:32:34 pm

---

Enliven raises $90M through sale of stock, warrants

 March 19, 2024 2:53:17 pm

---

Expenses grow as Enliven Therapeutics drug trials ramp up

 March 15, 2024 2:36:38 pm

---

Enliven Therapeutics expenses grow as R&D ramps up

 November 13, 2023 1:56:39 pm

---

R&D spending drove increased Enliven Therapeutics loss in Q2

 August 14, 2023 2:37:42 pm

---

Enliven Therapeutics files $200M shelf registration

 June 27, 2023 7:18:42 am

---

Enliven’s loss grows as drug trials progress

 May 12, 2023 3:08:04 pm

Next Page »